Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 249

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 249
---
 limitations on the review undertaken, is attached as Annex H hereto and is incorporated by reference herein in its entirety. The following summary of Newbridge’s opinion is qualified in its entirety by reference to the full text of the opinion. Newbridge delivered its opinion to the FutureTech Board for the benefit and use of the FutureTech Board (in its capacity as such) in connection with and for the purposes of its evaluation of the Business Combination from a financial point of view. Newbridge’s opinion also does not address the relative merits of the Business Combination as compared to any alternative business strategies or transactions that might exist for FutureTech, or the underlying business decision of FutureTech whether to proceed with those business strategies or transactions. Neither Newbridge’s written opinion nor the summary of its opinion and the related analyses set forth in this proxy statement/prospectus are intended to be, and do not constitute, advice or a recommendation to any FutureTech Stockholder as to how such FutureTech Stockholder should act or vote with respect to any matter relating to the proposed Business Combination or otherwise, including, without limitation, whether any such FutureTech Stockholder should redeem.

In connection with rendering its opinion, Newbridge, among other things:

| ● | considered                                                                                    
 our assessment of general economic, market and financial conditions as well as our experience 
 in connection with similar transactions, and business and securities valuations generally;    |

| ● | reviewed                                                                 
 a draft of the Merger Agreement, dated on or about September 11th, 2024; |

| ● | reviewed                                                                                  
 FutureTech’s publicly available historical financial results, as well as certain publicly 
 available information concerning the trading of, and the trading market for, the ordinary 
 shares of FutureTech since its initial public offering;                                   |

| ● | reviewed                                                                                   
 publicly available financial information of FutureTech filed with the U.S. Securities &    
 Exchange Commission, including its Form 10-Qs and certain reports on material events filed 
 on Forms 8-K between February 18th, 2022, and September 13th, 2024;                        |

| ● | conducted                                                                     
 discussions with Longevity’s management team to better understand Longevity’s 
 recent business history, and near-term financials;                            |

| ● | reviewed                                                                                       
 the financial models of Longevity’s different business units with historical data and          
 future financial projections (including potential timing of U.S. FDA regulatory approval       
 of their lead products, commercialization and sales schedules, as well as clinical development 
 budgets)